Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma
Conditions
Interventions
dexamethasone
lenalidomide
+1 more
Locations
14
Canada
Tom Baker Cancer Centre - Calgary
Calgary, Alberta, Canada
Cross Cancer Institute at University of Alberta
Edmonton, Alberta, Canada
British Columbia Cancer Agency - Centre for the Southern Interior
Kelowna, British Columbia, Canada
Moncton Hospital
Moncton, New Brunswick, Canada
Nova Scotia Cancer Centre
Halifax, Nova Scotia, Canada
Margaret and Charles Juravinski Cancer Centre
Hamilton, Ontario, Canada
Start Date
March 9, 2006
Primary Completion Date
June 30, 2008
Completion Date
June 30, 2008
Last Updated
August 4, 2023
NCT07319897
NCT00003353
NCT00002878
NCT00726830
NCT00534118
NCT00084747
Lead Sponsor
NCIC Clinical Trials Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions